These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 2328554)
1. The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. Razak TA; McNeil JJ; Sewell RB; Drummer OH; Smallwood RA; Conway EL; Louis WJ Clin Pharmacol Ther; 1990 Apr; 47(4):463-9. PubMed ID: 2328554 [TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. Ahmed JH; Grant AC; Rodger RS; Murray GR; Elliott HL Br J Clin Pharmacol; 1991 Jul; 32(1):57-62. PubMed ID: 1888642 [TBL] [Abstract][Full Text] [Related]
3. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis. Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of flecainide in patients with cirrhosis of the liver. McQuinn RL; Pentikäinen PJ; Chang SF; Conard GJ Clin Pharmacol Ther; 1988 Nov; 44(5):566-72. PubMed ID: 3141098 [TBL] [Abstract][Full Text] [Related]
5. The effect of hepatic disease on the disposition of moricizine in humans. Pieniaszek HJ; Davidson AF; McEntegart CM; Quon CY; Sampliner RE; Mayersohn M Biopharm Drug Dispos; 1994 Apr; 15(3):243-52. PubMed ID: 7880984 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers. Adams MH; Poynor WJ; Garnett WR; Karnes HT; Ferry JJ; Ryan KK; Sarkar MA Biopharm Drug Dispos; 1998 Nov; 19(8):501-15. PubMed ID: 9840212 [TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Everson G; Lasseter KC; Anderson KE; Bauer LA; Carithens RL; Wilner KD; Johnson A; Anziano RJ; Smolarek TA; Turncliff RZ Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):21S-26S. PubMed ID: 10771450 [TBL] [Abstract][Full Text] [Related]
8. Nicardipine infusion improved hepatic function but failed to reduce hepatic venous pressure gradient in patients with cirrhosis. Iwao T; Toyonaga A; Ikegami M; Sugawara H; Sumino M; Takagi K; Oho K; Sakaki M; Ohkubo K; Inoue R Am J Gastroenterol; 1992 Mar; 87(3):326-31. PubMed ID: 1539567 [TBL] [Abstract][Full Text] [Related]
9. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459 [TBL] [Abstract][Full Text] [Related]
10. A comparison between antipyrine and aminopyrine blood clearances. Kawasaki S; Imamura H; Kokudo N; Bandai Y; Sanjo K; Idezuki Y Hepatogastroenterology; 1992 Aug; 39(4):344-6. PubMed ID: 1427580 [TBL] [Abstract][Full Text] [Related]
11. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. Ferrara SD; Tedeschi L; Frison G; Orlando R; Mazzo M; Zordan R; Padrini R; Palatini P Eur J Clin Pharmacol; 1996; 50(4):305-10. PubMed ID: 8803524 [TBL] [Abstract][Full Text] [Related]
12. The association between rifamycin-SV (R-SV) related hyperbilirubinaemia and antipyrine clearance as a new test of liver function in cirrhosis. Persico M; Romano M; Villano N; Montella F; Gentile S Eur J Clin Invest; 1994 Mar; 24(3):201-4. PubMed ID: 8033955 [TBL] [Abstract][Full Text] [Related]
13. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Frost RW; Lettieri JT; Krol G; Shamblen EC; Lasseter KC Clin Pharmacol Ther; 1989 Jun; 45(6):608-16. PubMed ID: 2731404 [TBL] [Abstract][Full Text] [Related]
14. Enantioselective inhibitory effect of nicardipine on the hepatic clearance of propranolol in man. Vercruysse I; Belpaire F; Wynant P; Massart DL; Dupont AG Chirality; 1994; 6(1):5-10. PubMed ID: 8018468 [TBL] [Abstract][Full Text] [Related]
15. The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. Kitteringham NR; Büstgens L; Brundert E; Mineshita S; Ohnhaus EE Eur J Clin Pharmacol; 1984; 26(1):65-70. PubMed ID: 6714293 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. Hayes PC; Plevris JN; Bouchier IA J Hum Hypertens; 1989 Jun; 3 Suppl 1():153-8. PubMed ID: 2550638 [TBL] [Abstract][Full Text] [Related]
17. Reduced prehepatic extraction of nicardipine in the presence of pioglitazone in rats. Choi JS; Koh YY; Chung JH; Choi DH; Han HK J Pharm Pharmacol; 2008 Oct; 60(10):1403-7. PubMed ID: 18812034 [TBL] [Abstract][Full Text] [Related]
18. Theophylline disposition in patients with hepatic cirrhosis. Piafsky KM; Sitar DS; Rangno RE; Ogilvie RI N Engl J Med; 1977 Jun; 296(26):1495-7. PubMed ID: 865528 [TBL] [Abstract][Full Text] [Related]
19. Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate. Moore K; Zannikos P; Solanki B; Greenspan A; Verhaeghe T; Brashear HR J Clin Pharmacol; 2012 May; 52(5):738-46. PubMed ID: 21566203 [TBL] [Abstract][Full Text] [Related]
20. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. Kawasaki S; Sugiyama Y; Iga T; Hanano M; Beppu T; Sugiura M; Sanjo K; Idezuki Y Clin Pharmacol Ther; 1988 Aug; 44(2):217-24. PubMed ID: 3396264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]